Merck & Co (MRK) Financials: Revenue & Earnings

MRK$150.34—
Drug Manufacturers - GeneralMega CapHigh Quality
Compare
Market cap$329.65BEnterprise value—Revenue (TTM)$67.3BMarket positionTop 5%

Score

43
Bearish
Value
38
Quality
61
Growth
30

Financial Summary

Merck & Co., Inc. (MRK) last printed $150.34. Equity value is $329.65B. Trailing earnings multiple 133.40. The revenue row is reported history.

Financials

2016201720182019202020212022202320242025
$39.81B$40.12B$42.29B$39.12B$41.52B$48.7B$59.28B$60.12B$64.17B$64.93B

Merck & Co (MRK) Financials: Revenue & Earnings

MRK price $150.34 —

Ticker
MRK
Price
$150.34
Change
—
Market cap
$329.65B
P/E
133.40
Forward P/E
15.79
Dividend yield
2.26%
Beta
0.22
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
43
Value
38
Quality
61
Growth
30

Stocklytics score rationale: value 38, quality 61, growth 30.

AI Score 55. Merck & Co., Inc. has a high price-to-earnings ratio of approximately 153.4, indicating overvaluation relative to earnings

Summary

Merck & Co., Inc. operates in the Healthcare sector and Drug Manufacturers - General industry. The shares offer a dividend yield of 2.3%.

Valuation

The stock trades at a P/E ratio of 151.4 and a price-to-book ratio of 8.8. These multiples indicate a demanding valuation based on the provided measures.

Quality

Net margin is 3.6%, indicating profitability, though the provided information does not include balance-sheet, cash-flow, or return metrics.

Growth

No revenue, earnings-growth, estimate-revision, or price-trend data are provided, so growth cannot be assessed from the available facts.

Risks

The elevated P/E ratio of 151.4 creates valuation risk if earnings do not support the multiple. The net margin of 3.6% also provides limited evidence of profitability strength without additional operating context.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener